Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Aniracetam | Huperzine A | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 750-1500 mg/day divided into 2-3 doses | 50-200 mcg twice daily |
| Timing | With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat) | Morning and early afternoon. With or without food. |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off | Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation |
| Evidence Level | moderate_human | strong_human |
Potent positive allosteric modulator of AMPA receptors with 5-10x the potency of piracetam, slowing both channel closing rate and microscopic desensitization rates. Also modulates metabotropic glutamate receptors (mGluRs), activates nicotinic acetylcholine receptors, and indirectly boosts dopaminergic and serotonergic neurotransmission, conferring anxiolytic properties.
750-1500 mg/day divided into 2-3 doses
With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat)
Cycles of 8-12 weeks on, 4 weeks off
Potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), derived from the club moss Huperzia serrata. Exhibits preference for the tetrameric G4 form of AChE predominant in the mammalian brain. Eight-fold more potent than donepezil and two-fold more potent than rivastigmine at AChE inhibition. Crosses the BBB efficiently. Also antagonizes NMDA receptors at high concentrations and provides neuroprotection via attenuation of oxidative stress, regulation of apoptotic proteins (Bcl-2, Bax, P53, caspase-3), and upregulation of NGF.
50-200 mcg twice daily
Morning and early afternoon. With or without food.
Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →